ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Progression of Sub-Clinical Atherosclerosis

This study is ongoing, but not recruiting participants.

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00241787
  Purpose

To determine the rate of progression of sub-clinical cardiovascular disease as measured in carotid intimal medial thickness over a period of 8 to 10 years.


Condition
Atherosclerosis
Cardiovascular Diseases
Heart Diseases
Carotid Artery Diseases

MedlinePlus related topics:   Carotid Artery Disease    Heart Diseases   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Natural History, Defined Population

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date:   September 2005
Estimated Study Completion Date:   May 2010

Detailed Description:

BACKGROUND:

Strong associations exist between cardiovascular events and increased carotid artery wall intima-media thickness (IMT) as measured non-invasively by carotid ultrasound. Carotid IMT is accepted as a surrogate marker of sub-clinical cardiovascular disease.The study will determine the rate of progression of sub-clinical cardiovascular disease (change in IMT) over a period of 8 to 10 years.

DESIGN NARRATIVE:

The study will determine the rate of progression of sub-clinical cardiovascular disease (change in intimal medial thickness {IMT}) over a period of 8 to 10 years. Imaging and IMT measurements of approximately 2800 to 3000 members of the Framingham Offspring cohort having had baseline IMT measurements at their 1995-98 clinic visit will be repeated in 2005-2007. The principal aims of the project are to study the primary hypotheses that: 1. Interim exposure to traditional cardiovascular risk factors measured over 50 years is positively associated with the progression rate of carotid IMT. 2. Baseline carotid IMT and cumulative exposure to cardiovascular risk factors 20 years before the baseline visit are a better predictor of progression of sub-clinical disease after 8 to 10 years than the interim exposure to risk factors. 3. Novel risk factors such as C-reactive protein and homocysteine affect progression of carotid atherosclerosis more than traditional risk factors. This study will add a phenotypic marker of site-specific change in sub-clinical cardiovascular disease to the Framingham Study database. This complements ongoing research on the progression of sub-clinical cardiovascular disease and its associations with family history of premature cardiovascular events and genomic markers

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

No eligibility criteria

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241787

Sponsors and Collaborators

Investigators
Investigator:     Joseph Polak     New England Medical Center Hospitals, Inc.    
  More Information


Study ID Numbers:   1314
First Received:   October 17, 2005
Last Updated:   October 17, 2005
ClinicalTrials.gov Identifier:   NCT00241787
Health Authority:   United States: Federal Government

Study placed in the following topic categories:
Arterial Occlusive Diseases
Atherosclerosis
Heart Diseases
Vascular Diseases
Disease Progression
Central Nervous System Diseases
Arteriosclerosis
Brain Diseases
Carotid Artery Diseases
Cerebrovascular Disorders

Additional relevant MeSH terms:
Nervous System Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 17, 2008




Links to all studies - primarily for crawlers